Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Income from Continuing Operations came in at 63734000.0 in Q1 2026, up 12.33% YoY from 56737000.0 in Q1 2025, and up 2.22% on a QoQ basis from 62349000.0 in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Income from Continuing Operations data on file, last reported at 63734000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 12.33% year-over-year to 63734000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 230974000.0 (up 17.04% YoY) and the FY2025 annual result came in at 223977000.0, up 36.66% from the prior year.
- Income from Continuing Operations grew to 63734000.0 in Q1 2026, from 62349000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 63734000.0 in Q1 2026 to a low of 30764000.0 in Q3 2023.
- A 5-year average of 34604941.18 and a median of 37762000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 235.24% — and 2024, when it soared 242.65%.
- Tracing CPRX's Income from Continuing Operations over 5 years: stood at 25471000.0 in 2022, then plunged by 33.1% to 17039000.0 in 2023, then surged by 228.28% to 55936000.0 in 2024, then grew by 11.46% to 62349000.0 in 2025, then grew by 2.22% to 63734000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 63734000.0 (Q1 2026), 62349000.0 (Q4 2025), and 52783000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 63.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.73 Mn |
| Dec 31, 2025 | 62.35 Mn |
| Sep 30, 2025 | 52.78 Mn |
| Jun 30, 2025 | 52.11 Mn |
| Mar 31, 2025 | 56.74 Mn |
| Dec 31, 2024 | 55.94 Mn |
| Sep 30, 2024 | 43.88 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Mar 31, 2024 | 23.28 Mn |
| Dec 31, 2023 | 17.04 Mn |
| Sep 30, 2023 | -30.76 Mn |
| Jun 30, 2023 | 37.76 Mn |
| Mar 31, 2023 | 29.57 Mn |
| Dec 31, 2022 | 25.47 Mn |
| Sep 30, 2022 | 22.75 Mn |
| Jun 30, 2022 | 21.62 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 9.31 Mn |
| Sep 30, 2021 | 10.33 Mn |
| Jun 30, 2021 | 12.18 Mn |